deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
Company profile
Ticker
DCPH
Exchange
Website
CEO
Steven Hoerter
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Deciphera Pharmaceuticals, LLC
SEC CIK
Corporate docs
Subsidiaries
Deciphera Pharmaceuticals, LLC • Deciphera Pharmaceuticals Securities Corporation ...
DCPH stock data
Latest filings (excl ownership)
SC 14D9
Tender offer solicitation
13 May 24
SC TO-T
Third party tender offer statement
13 May 24
10-Q
2024 Q1
Quarterly report
10 May 24
SC TO-C
Information about tender offer
6 May 24
SC TO-C
Information about tender offer
30 Apr 24
SC14D9C
Written communication relating to third party tender offer
30 Apr 24
SC14D9C
Written communication relating to third party tender offer
29 Apr 24
SC14D9C
Written communication relating to third party tender offer
29 Apr 24
8-K
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
29 Apr 24
ARS
2023 FY
Annual report to shareholders
25 Apr 24
Transcripts
DCPH
Earnings call transcript
2023 Q4
6 Feb 24
DCPH
Earnings call transcript
2023 Q3
30 Oct 23
DCPH
Earnings call transcript
2023 Q2
9 Aug 23
DCPH
Earnings call transcript
2023 Q1
3 May 23
DCPH
Earnings call transcript
2022 Q4
7 Feb 23
DCPH
Earnings call transcript
2022 Q3
3 Nov 22
DCPH
Earnings call transcript
2022 Q2
7 Aug 22
DCPH
Earnings call transcript
2022 Q1
8 May 22
DCPH
Earnings call transcript
2021 Q4
9 Feb 22
DCPH
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
4
Change in insider ownership
24 Apr 24
4
Matthew L Sherman
20 Feb 24
4
Thomas Patrick Kelly
20 Feb 24
4
Jama Pitman
20 Feb 24
4
Steven L. Hoerter
20 Feb 24
4
Dashyant Dhanak
20 Feb 24
4
Daniel C. Martin
20 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
BRAIDWELL LP
14 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 91.23 mm | 91.23 mm | 91.23 mm | 91.23 mm | 91.23 mm | 91.23 mm |
Cash burn (monthly) | (no burn) | 1.95 mm | 16.28 mm | 17.21 mm | 18.20 mm | 12.65 mm |
Cash used (since last report) | n/a | 3.24 mm | 27.08 mm | 28.63 mm | 30.26 mm | 21.04 mm |
Cash remaining | n/a | 87.98 mm | 64.15 mm | 62.60 mm | 60.97 mm | 70.19 mm |
Runway (months of cash) | n/a | 45.1 | 3.9 | 3.6 | 3.4 | 5.5 |
Institutional ownership, Q4 2023
35.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 19 |
Opened positions | 2 |
Closed positions | 142 |
Increased positions | 3 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 16.88 bn |
Total shares | 30.59 mm |
Total puts | 0.00 |
Total calls | 200.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Brightstar Associates | 23.11 mm | $0.00 |
Flynn James E | 4.63 mm | $74.04 mm |
SVLSF Vi | 1.72 mm | $33.86 mm |
Assenagon Asset Management | 809.92 k | $13.06 bn |
Sunesis Advisors | 96.30 k | $1.55 bn |
DekaBank Deutsche Girozentrale | 50.00 k | $818.00 k |
SG Americas Securities | 43.72 k | $705.00 k |
Mirae Asset Global Investments | 41.53 k | $669.83 mm |
Nisa Investment Advisors | 22.94 k | $370.02 mm |
Allspring Global Investments | 21.38 k | $344.89 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Apr 24 | Brightstar Associates | Common Stock | Acquire X | No | No | 0.01 | 48,136 | 481.36 | 23,107,844 | |
22 Apr 24 | Brightstar Associates | Warrants Common Stock | Dispose X | No | No | 0.01 | 48,136 | 481.36 | 0 | |
7 Feb 24 | Brightstar Associates | Common Stock | Acquire X | No | No | 0.01 | 914,001 | 9.14 k | 23,059,708 | |
7 Feb 24 | Brightstar Associates | Warrants Common Stock | Dispose X | No | No | 0.01 | 914,001 | 9.14 k | 48,136 | |
16 Jan 24 | Daniel C. Martin | Common Stock | Sell | Dispose S | No | No | 14.4697 | 1,624 | 23.50 k | 47,660 |
16 Jan 24 | Squarer Ron | Stock Option Common Stock | Grant | Acquire A | No | No | 10.5783 | 4,727 | 50.00 k | 4,727 |
16 Jan 24 | Walsh Dennis Leo | Stock Option Common Stock | Grant | Acquire A | No | No | 10.5783 | 4,727 | 50.00 k | 4,727 |
News
Guggenheim Downgrades Deciphera Pharmaceuticals to Neutral
30 Apr 24
Deep Dive Into Deciphera Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)
30 Apr 24
Barclays Upgrades Deciphera Pharmaceuticals to Equal-Weight, Raises Price Target to $26
30 Apr 24
S&P 500 Edges Higher; ON Semiconductor Earnings Top Views
29 Apr 24
US Stocks Kick Off The Week In The Green, Tesla Rockets On China's FSD Approval, Yen Rallies: What's Driving Markets Monday?
29 Apr 24
Press releases
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, AGS, DCPH
20 May 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGS, HCP, DCPH
13 May 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DCPH, IONM, DPSI
10 May 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DCPH, HCP, TBNK
9 May 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DCPH, HTLF, DPSI, UNIT
4 May 24